The Chemours Company cash flow to debt ratio of 5.76% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

The Chemours Company's free cash flow has increased 105.14% from $-993.00M last year to $51.00M, signaling increasing performance

The Chemours Company's debt to equity ratio is 25.97, which means that the company's assets are unhealthy financed, signaling financial risk.

The Chemours Company's debt has increased relative to shareholder equity from 7.21 last year to 25.97 today, signaling weakened financials

The Chemours Company has a net debt to EBITDA ratio of 11.79x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

The Chemours Company's interest coverage ratio is -0.65, which means that the company struggles to meet interest obligations, signaling financial risk.

The Chemours Company's profit margin was 1.49% last year and is -2.88% this year, signaling decreasing performance

The Chemours Company's short-term assets of $3.00B exceed its short-term liabilities of $1.69B

The Chemours Company's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

The Chemours Company's return on equity of -117.69%, is lower than 15.00%, indicating bad performance

The Chemours Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

The Chemours Company had positive net income in 3 out of 5 years, indicating stable and consistent earnings

The Chemours Company has positive free cash flow, indicating the company generates cash after capital expenditures

The Chemours Company has a free cash flow yield of 2.66%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

The Chemours Company's yearly earnings has decreased 548.84% since last year from $86.00M to $-386.00M, signaling decreasing performance

The Chemours Company's yearly revenue has increased 0.45% since last year from $5.78B to $5.81B, signaling increasing performance

ROIC 10.06% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

The Chemours Company's 3-year revenue CAGR of -5.26% is negative, indicating declining revenue over the past 3 years

The Chemours Company had revenue growth in 3 out of 5 years, indicating consistent revenue performance

The Chemours Company had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

The Chemours Company is overvalued relative to its fair value price of 5.14 based on Base Cash Flow Valuation (DCF) model

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

The Chemours Company has an EV/EBITDA ratio of 17.57x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

The Chemours Company is undervalued relative to its fair value price of 39.44 based on Base Earnings Fair Value model

The Chemours Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

The Chemours Company has a price-to-book ratio of 12.37x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

The Chemours Company has a price-to-sales ratio of 0.33x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue